Sort   by:  
 Page size 
TranscriptomicsSimvastatin treated Lymphoblastoid Cell lines from Cholesterol and Pharmacogenomics (CAP) Trial
Statins reduce cardiovascular disease risk by lowering plasma low density lipoprotein (LDL)-cholesterol. To identify novel pathways that modulate statin response, we assessed the influence of simvastatin exposure on expression quantitative trait locus (eQTL) associations across the genome in 480 ly...
ORGANISM(S): Homo sapiens 
2012-06-30 | E-GEOD-36868 | biostudies-arrayexpress
GenomicCholesterol and Pharmacogenetics (CAP) Study

The Cholesterol and Pharmacogenetics Study was a 6-week open label, non-randomized study of 40mg/day simvastatin treatment in 335 African-American and 609 Caucasian (944 total) men and women. Plasma lipids and lipoproteins were measured on two occasions prior to treatment and at 4 and 6 weeks of ...

phs000481 | dbGaP
Sort   by:  
 Page size